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mean LDL-C reduction and difference in event rate between
statin and placebo arms in published outcomes studies (4S,
CARE, LIPID, HPS), was performed for major clinical endpoints.
A model was developed to estimate LDL-C reductions using
alternative baseline LDL-C values and the weighted mean differ-
ence (WMD) from the meta-analysis. These were combined with
results from regression analyses to calculate percentage reduction
in cardiovascular events and impact estimated for a population
of 100,000. The model was also run using the 95% conﬁdence
intervals from the meta-analysis. RESULTS: Meta-analysis
demonstrated a signiﬁcant reduction in LDL-C in favour of rosu-
vastatin 40 mg (WMD –5.26%, 95% CI: –6.08% to –4.43%;
p < 0.00001). There was no signiﬁcant heterogeneity identiﬁed in
the meta-analysis (p = 0.42) with low inconsistency in trial
results (I2 = 2.1%). Regression analyses showed good correla-
tion (R2 > 0.65) between LDL-C reduction and percentage dif-
ference in event rates for coronary death, major coronary event,
non-fatal myocardial infarction (MI) and revascularisations
(CABG and PCTA). Simulations using alternative LDL-C distri-
butions with means varying from 3.40–7.56 mmol/L generated
LDL-C reductions of 1.68–3.78 and 1.85–4.18 for rosuvastatin
20 mg and 40 mg, respectively. These values translated into the
following reductions depending on the mean of the distribution:
0.33%–0.74% coronary deaths; 0.72%–1.62% major coronary
events; 0.52%–1.17% non-fatal MIs; 0.59%–1.32% revasculari-
sation procedures. Based on a population of 100,000, the incre-
mental beneﬁt of rosuvastatin 40 mg over 20 mg resulted in the
prevention of 329–742 coronary deaths, 721–1,624 major coro-
nary events, 517–1,165 non-fatal MIs and 586–1,321 revascu-
larisation procedures. CONCLUSION: Rosuvastatin 40 mg
reduces LDL-C signiﬁcantly more than 20 mg. Modelled out-
comes suggest this may translate into substantially fewer
cardiovascular-related events.
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OBJECTIVES: With the lowering of the recommended choles-
terol levels in Europe, use of lipid lowering drugs has become a
more important clinical option. The study aim was to determine
total cholesterol levels by type of lipid lowering therapy in the
primary care setting in France, Italy and the UK. METHODS:
The study populations were identiﬁed from the THALES
(France, Italy) and The Health Improvement Network “THIN”
(UK) primary care databases. Patients were included if they
received a ﬁbrate or statin prescription in the ﬁrst 6 months of
2005 (index), had a prescription at least 6 months before index
and had a valid cholesterol record during the 12 months after
index. To account for differing cholesterol reporting habits,
analyses were restricted to general practitioners with cholesterol
reporting rate >50%. Multivariate linear regression was applied
to compare the effect of drug type on cholesterol level by country.
RESULTS: The rates of statin use were 71%, 88% and 97% for
France, Italy and the UK respectively. In France, the median
cholesterol was 5.2 mmol/L among statin users (n = 22674;
mean age = 65; male = 57%) compared to 5.3 mmol/L among
ﬁbrate users (n = 9283; age = 66; male = 46%). In Italy,
the median cholesterol was 5.2 mmol/L among statin users
(n = 4822; age = 67; male = 48%) compared to 5.4 mmol/L
among ﬁbrates users (n = 641; age = 65; male = 56%). In the
UK, median cholesterol was 4.4 mmol/L among statin users
(n = 113252; age = 67; male = 55%) compared to 5.1 mmol/L
among ﬁbrate users (n = 3626; age = 65; male = 49%). For each
country, statin therapy was associated (p < 0.001) with lower
median cholesterol level after controlling for age, gender, dia-
betes and coronary heart disease. CONCLUSION: The use of
statins in primary care was dominant in all countries studied,
although prescribing habits varied. Cholesterol levels were lower
among statin users than ﬁbrate users and this difference was
greatest in the UK.
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EPROSARTANVERSUS OTHER ANGIOTENSIN-RECEPTOR
BLOCKERS COMMONLY USED IN POLAND IN PATIENTS
WITH HYPERTENSION-INDIRECT ANALYSIS
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OBJECTIVES: To compare the clinical effectiveness of eprosa-
rtan and irbesartan, losartan, telmisartan and valsartan in
patients with hypertension. METHODS: The clinical effective-
ness analysis in accordance with the Cochrane Collaboration
guidelines were performed. In the absence (or lack of sufﬁcient
data) of RCT making head-to-head comparisons of eprosartan
vs other angiotensin-receptor blockers meta-analysis based on
an indirect comparison was performed, using placebo as the
common comparator (Bucher method). RESULTS: Eprosartan
vs losartan- Because of the lack of sufﬁcient data, indirect
analysis was performed. Compared drugs was comparable in
terms of efﬁcacy. In the safety analysis no signiﬁcant differences
were observed between groups except withdrawal due to
adverse events which was more common in losartan group OR
0.46 (95%CI: 0.23; 0.96). Eprosartan vs telmisartan- Indirect
analysis showed that there is now statistically signiﬁcantly dif-
ference in change systolic pressure. There was statistically sig-
niﬁcant difference between groups on favors telmisartan in
achieving clinical response OR 0.42 (95%CI: 0.23; 0.76).
Safety of both interventions was the same. Eprosartan vs val-
sartan or irbesartan: Analysis based on indirect evidence
showed no signiﬁcant differences between the groups in terms
of efﬁcacy (change in systolic and diastolic pressure, response
to treatment).The incidence of adverse events was similar in
compared groups. CONCLUSION: Analysis suggests that epro-
sartan has comparable efﬁcacy to losartan, valsartan, irbe-
sartan. Telmisartan is more effective compared with eprosartan
for treatment of patients with hypertension. Safety of interven-
tions is comparable. However, results based on indirect evi-
dence need to be viewed cautiously.
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OBJECTIVES: This study compares the differences in incidences
of hospitalisations for cardiovascular events between users of
selected statins. METHODS: New statin users between January
1, 2000 and September 30, 2005 were extracted from the
PHARMO database (population 3 million) and followed for
maximally two years after start of statin use, up to December 31,
2005. Incidences of hospitalisations for fatal and non-fatal car-
diovascular disease (CVD) in general (including ischemic heart
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disease and strokes), and for myocardial infarctions (MI) spe-
ciﬁcally, occurring during the use of the initially prescribed
statin were compared between different statins using multivari-
ate Cox-regression analysis. RESULTS: Included new statin
users started with simvastatin (32824 (35%)), atorvastatin
(30849 (33%)), pravastatin (19652 (21%)), or rosuvastatin
(8710 (9%)). Average doses were 23 mg, 19 mg, 35 mg and
11 mg respectively. Thirty-ﬁve (percent) were considered to be
at increased risk of cardiovascular events due to pre-existing
CVD or diabetes. The median duration of follow up and initial
statin therapy were two years and 48 weeks respectively. The
incidence per 100 person years of fatal and non-fatal CVD
and MI respectively were 3.2 and 0.4 for rosuvastatin, 4.5 and
0.6 for atorvastatin, 4.1 and 0.7 for simvastatin, and 6.5 and
1.0 for pravastatin. Different multivariate models and adjust-
ment methods were used to study whether the observed
differences could be explained by bias or confounding. None of
these adjustments or models altered the observed risk differ-
ences substantially. CONCLUSION: We observed substantial
differences in incidence rates of hospitalisations for cardiovas-
cular events between users of different statins, independent
from dosing and preferences in prescribing of statins. The
lowest incidence of hospitalizations due to cardiovascular
events were observed among users of rosuvastatin followed by
atorvastatin, simvastatin and pravastatin. These ﬁndings
suggest that the greater LDL-C reductions offered by rosuvas-
tatin may translate into additional beneﬁts in lower rates of
cardiovascular events.
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OBJECTIVES: 1.) To ﬁnd efﬁciency Hierarchical Stepwise Mul-
tiple Regression Analysis model that predict diastolic blood
pressure. 2.) To ﬁnd correlation between calories burnt by exer-
cise, compliance, eating behavior score, hypertension knowl-
edge and diastolic blood pressure. METHODS: A cross-
sectional clinical and survey study by face to face interview
with questionnaire was employed to investigate relationship
between health behavior factors namely—calories burnt by
exercise, compliance, eating behavior score, smoking, drinking,
demographic data and diastolic blood pressure of 200 hyper-
tension patients at Adisorn Hospital selected by convenient
sampling. RESULTS: Total sample size (n = 200, 100%) of
hypertension patients, mostly 113 (56.50%) were female,
87 (43.50%) were male with average age 57.29  13.16
years, Average BMI 27.52  3.84, Average total calories burnt
per week 1749.68  3948.43, Average compliance score
7.85  2.12, Average hypertension knowledge score 7.06 
0.58, Average eating behavior score 6.91  1.97, and average
Diastolic 94.11  11.11. Compliance score and hypertension
knowledge had signiﬁcantly correlated with Diastolic (r = 0.97,
-0.13, p < 0.01). Hierarchical stepwise Multiple Regression
Analysis conﬁrmed that 3 factors—calories burnt by exercise,
compliance score and age were signiﬁcantly predictors of Dias-
tolic (Beta = 0.56, 0,42, 0.05, p < 0.01, R Square = 0.86).
CONCLUSION: Hierarchical Stepwise Multiple Regression
Analysis conﬁrmed that calories burnt by exercise, compliance
and age were three signiﬁcantly factors predicted diastolic
blood pressure.
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OBJECTIVES: To evaluate the degree of interrelation among
cardiovascular risk factors (CVRF), and routine achievement of
some therapeutic goals for modiﬁable CVRF in primary care
settings. METHODS: Multicentric-retrospective study. Data
were obtained from 5 primary care setting clinic records (patients
>30 years old) during 2006. Patients were divided into 8 groups,
including combinations of the three main modiﬁable CVRF. Cri-
teria: NCEP-ATP III modiﬁed. Main measures: cardiovascular/
general diagnostics, cardiovascular events (CVE), clinical
parameters (systolic and diastolic blood pressure, cholesterol
levels, LDLc levels, etc) and costs (semi ﬁxed/variable, tests,
derivation, drugs). ANCOVA analyses were developed (Bonfer-
roni adjust) to correct the model. SPSS program was used. A
signiﬁcance level of , p < 0.05 was used RESULTS: In total,
57,025 patients were studied, age: 54.3  16,2 years old, 54.8%
women; CVE: 8.8%. Distribution by groups: a) population:
55.3% (n = 31,554; age: 47.2  14.1 years old; women: 55.7%;
ECV: 3.1%), b) Hypertension (HT): 11,6% (n = 6627; age:
66,9  13,8 years old; women: 57.4%; CVE: 14.4%), c) Diabe-
tes Mellitus DM): 2.6% (n = 1465; age: 60.1  16.4 years old;
women: 44.4%; CVE: 16.8%), d) Dyslipidemia (DL): 13.7%
(n = 7811; age: 55.2  13.2 years old; women: 50.5%; CVE:
8.2%), e) HT-DM: 2.8% (n = 1624; age: 71.2  11.8 years
old; women: 55.5%; CVE: 25.4%), f) HT-DL: 8.3% (n = 4707;
age: 66.5  11.7 years old; women: 57.3%; ECV: 19.1%), g)
DM-DL: 1.9% (n = 1058; age: 63.5  11.8 years old; women:
41.7%; ECV: 23.3%) y h) HT-DM-DL: 3.8% (n = 2179; age:
69.1  10.2 years old; women: 55.5%; CVE: 30.6%), p < 0.001.
DM-DL and HT-DM-DL groups had the worst metabolic
controls. All components of costs were higher in the HT-
DM and HT-DM-DL groups; 1543.60  1232.33 y 1739.07 
1192.35€, respectively (p < 0.001). CONCLUSION: Diabetes
mellitus is the main risk factor (greater presence in CVE) and is
associated with worse metabolic status and higher cost of care.
Achievement of established therapeutic goals must be improved
in primary care.
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OBJECTIVES: The aim of our study is to analyse the validity
of administrative data and the appropriateness, accessibility
and effectiveness of acute myoardial infarction (AMI) care.
METHODS: Data derive from the nationwide database of the
National Health Insurance Fund Administration (OEP). Our
tudy includes patients admitted to a hospital between 2000 and
2005 due to AMI (ICD 10, I21 or I22) or were treated by
reperfusion or revascularisation therapy (PCI, thrombolysis,
CABG—intervention group). The mortality data was derived
from death certiﬁcates. We analysed the role of risk factors by
logistic regression. RESULTS: From 2000 until 2005 the number
of AMI cases has increased from 14089 to 16296 (n = 92902)
while the 30-day mortality of AMI cases decreased from 20.9%
to 19.2% (P < 0.001). In 2000, 30.3% of the AMI cases were
treated with PCI, thrombolysis or CABG, this proportion
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